Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri bought 240,000 shares of the stock in a transaction dated Friday, February 7th. The stock was bought at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the acquisition, the insider now directly owns 2,884,121 shares of the company's stock, valued at approximately $14,420,605. This represents a 9.08 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Marlio Charles Mosseri also recently made the following trade(s):
- On Friday, December 13th, Marlio Charles Mosseri bought 17,000 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $4.70 per share, for a total transaction of $79,900.00.
Nuvectis Pharma Price Performance
Shares of NVCT stock traded up $0.85 during mid-day trading on Friday, hitting $7.80. The company had a trading volume of 220,480 shares, compared to its average volume of 106,046. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $12.10. The stock's 50 day moving average price is $5.80 and its 200-day moving average price is $6.36. The company has a market capitalization of $150.70 million, a P/E ratio of -6.72 and a beta of 0.22.
Hedge Funds Weigh In On Nuvectis Pharma
Hedge funds have recently modified their holdings of the stock. Iridian Asset Management LLC CT purchased a new stake in Nuvectis Pharma during the third quarter valued at $348,000. Nations Financial Group Inc. IA ADV purchased a new stake in Nuvectis Pharma during the third quarter valued at $63,000. GSA Capital Partners LLP raised its stake in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company's stock valued at $315,000 after purchasing an additional 1,790 shares in the last quarter. Geode Capital Management LLC raised its stake in Nuvectis Pharma by 49.8% during the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company's stock valued at $501,000 after purchasing an additional 26,489 shares in the last quarter. Finally, Baldwin Wealth Partners LLC MA raised its stake in Nuvectis Pharma by 104.4% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company's stock valued at $1,926,000 after purchasing an additional 181,831 shares in the last quarter. Hedge funds and other institutional investors own 96.77% of the company's stock.
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Read More
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
